US Patent

US7879842 — Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it

Method of Use · Assigned to Les Laboratoires Servier SAS · Expires 2026-02-22 · 0y expired

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a beta-crystalline form of ivabradine hydrochloride and a process for its preparation, useful as a bradycardic.

USPTO Abstract

Î²-Crystalline form of ivabradine of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as bradycardics.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1694`	—	ivabradine-hydrochloride
`U-1694`	—	ivabradine-hydrochloride
`U-1694`	—	Corlanor

Patent Metadata

Patent number: US7879842
Jurisdiction: US
Classification: Method of Use
Expires: 2026-02-22
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Les Laboratoires Servier SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.